QIAGEN and Servier Will Develop CDx for Acute Myeloid Leukemia Therapy Drug
QIAGEN and Servier are partnering to develop a CDx test for TIBSOVO, an isocitrate dehydrogenase-1 inhibitor indicated for AML treatment.
Read MorePosted by Andy Lundin | Mar 10, 2023 | Leukemia |
QIAGEN and Servier are partnering to develop a CDx test for TIBSOVO, an isocitrate dehydrogenase-1 inhibitor indicated for AML treatment.
Read MorePosted by Andy Lundin | Mar 9, 2023 | Leukemia |
Research shows benefits of screening patients in remission from acute myeloid leukemia for residual disease prior to a bone marrow transplant.
Read MorePosted by Andy Lundin | Dec 30, 2022 | Leukemia |
Alercell is launching a leukemia diagnostic test based on sequencing DNA that will detect up to 51 Genes mutations in Leukemia patients.
Read MorePosted by Andy Lundin | Jun 28, 2022 | Leukemia |
Everyone has a small number of an unusual thymocyte cell, which can become a form of leukemia called T-cell acute lymphoblastic leukemia.
Read MorePosted by Andy Lundin | Mar 8, 2022 | Leukemia |
To better treat patients with acute myeloid leukemia, researchers discovered a novel subtype of the cancer via proteome and genetic analysis.
Read More